Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2 Active not recruiting

83 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06802757 2026-02-25

PRISM-TNBC

Phase 2 Recruiting

72 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

85 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Phase 2 Completed

29 enrolled 15 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07394387 2026-02-06

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Phase 2 Recruiting

39 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06027268 2026-02-03

ToPCourT

Phase 2 Active not recruiting

36 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07283692 2026-02-03

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Phase 2 Not yet recruiting

46 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06279364 2026-01-27

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 3 Recruiting

524 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06400472 2026-01-14

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Phase 1 Recruiting

495 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Breast

Triple Negative Breast Neoplasms

NCT06351332 2026-01-12

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Phase 1/2 Active not recruiting

78 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

I-SPY

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

TroFuse-011

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

TELESCOPE

KEYLYNK-009

RAINFOL-01

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

PRISM-TNBC

MK-5890-003

TARMAC

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

ToPCourT

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

neoMono

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC